Indication
Progressive Systemic
1 clinical trial
2 products
Product
Oral PlaceboClinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)Status: Recruiting, Estimated PCD: 2025-12-01
Product
Ifetroban